600196 Shanghai Fosun Pharmaceutical
- 25.15
- +1.20+5.01%
Shanghai Fosun Pharmaceutical News
Fosun Pharmaceuticals: Fosun Pharmaceuticals: Legal Opinion of Attorney Guo Hao (Shanghai) Office on the implementation of partial restricted stock repurchases and cancellation of the 2022 Restricted A-share Stock Incentive Plan of Shanghai Fosun Pharmaceuticals (Group) Co., Ltd.
Fosun Pharmaceutical\'s announcement on the implementation results of the A-share repurchase and changes in share structure
Fosun Pharmaceuticals: Legal Opinion of Attorney Guo Hao (Shanghai) Office on the implementation of partial restricted stock repurchases and cancellation of the 2022 Restricted A-share Stock Incentive Plan of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Fosun Pharmaceutical\'s Announcement on the Implementation of Repurchase and Cancellation of Certain A-Share Restricted Shares
Announcement of Fosun Pharmaceutical on the implementation results of the controlling shareholder\'s plan to increase the company\'s share holdings
Announcement of Fosun Pharmaceutical on increasing the shareholding of Fosun Kate Biotechnology Co., Ltd. and revising and restating the license agreement
Fosun Pharmaceutical\'s announcement on the progress of share repurchase
Fosun Pharmaceutical\'s indicative announcement on share repurchase progress and H share repurchase plan
Fosun Pharma's Notice to Creditors Regarding Repurchase and Cancellation of Restricted Stocks of Part A Shares.
Announcement on Fosun Pharma's repurchase and cancellation of restricted stocks of A shares with unresolved restrictions.
Shanghai Fosun Pharmaceutical: Legal opinion of Guohao Law Firm (Shanghai) on the cancellation of restricted stocks of Shanghai Fosun Pharma (Group) Co., Ltd.'s 2022 restricted A-share stock incentive plan repurchase.
Fosun Pharma's announcement regarding the progress of repurchasing shares through centralized bidding trading and the adjustment of the repurchase price limit after the implementation of the 2023 equity distribution.
Announcement regarding the implementation subject of the newly raised investment projects in the non-public issuance of Fosun Pharma in 2022.
Fosun Pharma's 2023 Annual A-share Equity Distribution Implementation Announcement.
Announcement of Fosun Pharma on the pledging and release of part of its shareholders' shares
Announcement on the Progress of Fosun Pharma's Repurchase of Shares through Concentrated Bidding Trading
Announcement of Fosun Pharma's First Repurchase of A-shares via Centralized Bidding Trading
Announcement on the proposed sale of 6.01% of the equity interest in Gland Pharma Limited, a subsidiary in which Fosun Pharma holds controlling equity interests.
Announcement on the Progress of Fosun Pharma's Repurchase of Shares through Concentrated Bidding Trading
Announcement of Fosun Pharmaceutical on increasing its shareholding in Foshan Xinglian Nursing Home Co., Ltd. and related transactions
Analysis
Price Target
No Data
No Data